Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical company, Polaris Group, has announced its plans to invest $50m in Taiwan to establish an anti-cancer protein-injection factory.
Subscribe to our email newsletter
The company will produce ADI-PEG 20 products and targets an annual production value of around $2bn, news.cens.com reported.
Polaris developed ADI-PEG 20 drug for the treatment of cancers.
The US FDA has conferred orphan drug status upon the drug which has completed Phase 2 clinical trial in Taiwan.
ADI-PEG 20 is set to enter Phase 3 trial.